Paricalcitol

Generic Name: Paricalcitol

Brand Names: Zemplar

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₄₄O_₃

CAS Number: 131918-61-1

Unique Ingredient Identifier: 6702D36OG5

Background: Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.

Indication: For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4

Associated Conditions: Secondary Hyperparathyroidism (SHPT)

Clinical Trials

Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients

Phase 4

Completed

Conditions: Kidney Failure

Interventions: Drug: Paricalcitol

First Posted Date: 2006-02-22

Last Posted Date: 2010-04-08

Lead Sponsor: Fresenius Medical Care North America

Target Recruit Count: 64

Registration Number: NCT00294866

Locations: 🇺🇸
Nephrology Center, Kalamazoo, Michigan, United States
🇺🇸
Delaware Valley Nephrology, Philadelphia, Pennsylvania, United States
🇺🇸
Nephrology Associates, PC, Nashville, Tennessee, United States

and more 3 locations

Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders

Phase 1

Terminated

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2005-11-24

Last Posted Date: 2013-02-01

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 7

Registration Number: NCT00258258

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease

Phase 4

Completed

Conditions: Chronic Kidney Disease, Stage 5
Secondary Hyperparathyroidism

Interventions: Drug: Zemplar® injection
Drug: Hectorol® injection

First Posted Date: 2005-11-24

Last Posted Date: 2009-12-24

Lead Sponsor: Abbott

Target Recruit Count: 41

Registration Number: NCT00257920

Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: gemcitabine hydrochloride
Drug: paricalcitol

First Posted Date: 2005-09-22

Last Posted Date: 2014-12-09

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 34

Registration Number: NCT00217477

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Zemplar® Capsule in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal Dialysis

Phase 3

Completed

Conditions: Kidney Disease

First Posted Date: 2004-09-22

Last Posted Date: 2011-01-19

Lead Sponsor: Abbott

Target Recruit Count: 78

Registration Number: NCT00091975

Locations: 🇺🇸
St. Louis University, St. Louis, Missouri, United States
🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸
University of Florida, Gainesville, Florida, United States

and more 13 locations

Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects on Hemodialysis

Phase 4

Completed

Conditions: Kidney Failure, Chronic

First Posted Date: 2004-09-13

Last Posted Date: 2007-09-26

Lead Sponsor: Abbott

Target Recruit Count: 201

Registration Number: NCT00091481

Locations: 🇬🇷
General Hospital of Heraklion, Voutes, Heraklion, Crete, Greece
🇬🇷
General Hospital of Melissia "Amalia Fleming", Melissia, Athens, Greece
🇬🇷
General University Hospital of Alexandroupolis, Dragana, Greece

and more 16 locations

Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium

Phase 4

Completed

Conditions: Secondary Hyperparathyroidism
Chronic Kidney Disease

First Posted Date: 2003-12-04

Last Posted Date: 2006-08-02

Lead Sponsor: Abbott

Target Recruit Count: 30

Registration Number: NCT00073710

Locations: 🇺🇸
Creighton University, Omaha, Nebraska, United States

Paricalcitol in Treating Patients With Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

First Posted Date: 2003-07-09

Last Posted Date: 2018-01-29

Lead Sponsor: Cedars-Sinai Medical Center

Registration Number: NCT00064376

Locations: 🇺🇸
Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California, United States

Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis

Phase 4

Terminated

Conditions: End-Stage Kidney Disease

First Posted Date: 2003-06-13

Last Posted Date: 2006-08-02

Lead Sponsor: Abbott

Target Recruit Count: 2200

Registration Number: NCT00062699

Locations: 🇺🇸
Gambro Healthcare - Los Angeles, Los Angeles, California, United States
🇺🇸
Paul Light, University of Maryland, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

and more 56 locations

Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis

Phase 4

Completed

Conditions: Secondary Hyperparathyroidism
End Stage Renal Disease

First Posted Date: 2003-02-03

Last Posted Date: 2006-08-02

Lead Sponsor: Abbott

Target Recruit Count: 28

Registration Number: NCT00053547

Locations: 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
Miami Children's Hospital, Miami, Florida, United States

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy